Highlights

• Chimeric Therapeutics (ASX:CHM) is committed to bringing novel and potentially transformative therapies to cancer patients.
• CHM advanced its clinical program with a new patent and crucial team appointments during the September quarter.
• The company secured a Japanese patent for CLTX CAR T, a novel and promising CAR T therapy under development for solid tumours.

Chimeric Therapeutics (ASX:CHM) is an Australian leader in cell therapy with CHM 1101 (CLTX CAR T), CHM 2101 (CDH17 CAR T) and CHM 0201 (CORE-NK platform) in its clinical development pipeline.

Image source: Company update

© 2022 Kalkine Media®

The ASX-listed clinical-stage company is committed to developing its pipeline with novel cell therapy assets for curing cancer patients.

The September quarter of 2022 saw major additions to the company’s team and a new patent covering the CLTX CAR technology. Chimeric ended the quarter with cash and cash equivalent of AU$8 million.

Japanese patent for CLTX CAR technology

In August, Chimeric secured a patent from the Japan Patent Office. The patent number JP 7,085,990 is entitled “Chimeric antigen receptors containing a chlorotoxin domain.”

The patent covers certain applications of chimeric antigen receptor (CAR) technology using chlorotoxin (CLTX). It also covers Chimeric’s clinical-stage CAR T asset CHM 1101 and preclinical-stage CAR NK asset CHM 1301.

Chimeric holds the exclusive worldwide licence to develop and commercialise JP 7,085,990 and associated patent applications filed in other countries.

New Chief Medical Officer 

In July, the company made a new appointment to the position of Chief Medical Officer (CMO). The newly appointed CMO Dr Jason B Litten has more than 15 years of leadership in drug development. In the last five years, Dr Litten was dedicated to advancing NK and CAR T cell therapy clinical-stage programs in oncology.

Prior to joining Chimeric, he served at Artiva Biotherapeutics as CMO. At Artiva, he led the development of a portfolio of allogeneic Natural Killer (NK) cell therapies.

Dr Litten has also served as the Vice President of Clinical Development at Juno Therapeutics, where he developed and guided the autologous solid tumour CAR T and TCRs cell therapy programs.

New Vice President - Clinical Operations and Data Management

Further, in July, Chimeric appointed Ms Cassandra Harrison to the position of Vice President of Clinical Operations and Data Management. Ms Harrison has more than a decade of expertise in data management, compliance, and clinical operations.

Ms Cassandra previously worked at ImmunoGenesis Inc. and Bellicum Pharmaceuticals. In her previous roles, she oversaw data management and outsourcing of several clinical programs and managed organisation resources. At Bellicum, she was also part of a pioneering team exploring CAR T therapies in solid tumours.

New Vice President - Translational Sciences

In September, Chimeric welcomed Dr Stephanie H. Astrow as Vice President, Translational Sciences. Enriched with more than two decades of experience in cell therapy and biotechnology, Dr Astrow has previously worked at Kite Pharma and Fate Therapeutics.

At Kite, Dr Astrow oversaw solid tumour programs, including strategic partnerships with the National Cancer Institute. She served in several leadership positions at different organisations, engaging in the approvals of various clinical assays, including molecular and companion diagnostics used in cancer therapy selections.

CHM shares were trading at AU$0.083 midday on 9 November 2022.